68
Markets3h 33m ago

Dyadic is highlighting increasing interest in its C1 protein production platform due to global infectious disease preparedness efforts responding to an ongoing Bundibugyo Ebola virus (BDBV) outbreak and expanding commercial adoption.

Archive Window: 7 Days Left

Jupiter, Florida

Who
Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions, Mark A. Emalfarb, Scripps Research, CEPI, Fondazione Biotecnopolo di Siena, European Vaccines Hub, the Gates Foundation
What
Dyadic is highlighting increasing interest in its C1 protein production platform due to global infectious disease preparedness efforts responding to an ongoing Bundibugyo Ebola virus (BDBV) outbreak and expanding commercial adoption.
When
Mon, 15 Jun 2026 11:28:03 GMT · 3h 33m ago
Where
Jupiter, Florida ·
Why
The Bundibugyo Ebola virus outbreak has intensified global infectious disease preparedness, renewing focus on rapidly manufacturing vaccines and antibodies, which Dyadic's C1 platform aims to address.
The Frontline Impact

How this affects you

The ongoing Bundibugyo Ebola virus outbreak is driving increased demand for rapid, scalable vaccine and antibody manufacturing solutions. Dyadic's C1 biomanufacturing platform is positioned to address this critical need, potentially accelerating the development and production of countermeasures for Ebola and other infectious diseases.

Story chain

3 events in this thread
  1. Markets3h 33m ago
    Dyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.
    Open article
  2. Currently Reading3h 33m ago
    Dyadic is highlighting increasing interest in its C1 protein production platform due to global infectious disease preparedness efforts responding to an ongoing Bundibugyo Ebola virus (BDBV) outbreak and expanding commercial adoption.
  3. Markets3h 33m ago
    Dyadic's C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets.
    Open article

Verified Sources & Citations